The generic name of Miguda is zoledronic acid, and its efficacy and action are mainly used for the treatment of osteoporosis in postmenopausal women, and also used for the treatment of deforming osteitis. Zoledronic acid belongs to nitrogen-containing bisphosphonic acid compounds, which mainly acts on human bones, can inhibit osteoclasts and inhibit bone resorption, and it has a high affinity for mineralized bone and acts selectively on bones to increase bone density. Based on the above pharmacological effects, it is clear that zoledronic acid is used to treat osteoporosis and deforming osteitis in postmenopausal women. However, the drug also has certain side effects, such as insomnia, headache, loss of appetite, conjunctivitis, rash, myalgia and so on, and even cause systemic symptoms such as fever. The use of zoledronic acid must be strictly controlled by the indications, and must be under the guidance of professional doctors.